| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
HCV (Hepatitis C Virus) protease; also targets inflammatory pathways and immune modulation.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate antiproliferative activity against rat HSC-T6 cells with an IC50 of 8240.0 nM after 48-hour incubation in MTT assay. Deapioplatycodin D regulates airway mucin production and secretion, partly explaining its traditional use as an expectorant in inflammatory pulmonary diseases. It also exhibits anti-inflammatory activity in vitro.
|
| ln Vivo |
In vivo, Deapioplatycodin D shows potential in inhibiting viral replication and reducing inflammation, supporting respiratory health in viral infections. Its immune-modulatory effects enhance antiviral defense mechanisms. However, detailed in vivo pharmacokinetic and efficacy data remain limited in publicly available literature.
|
| Enzyme Assay |
No specific cell-free enzyme/receptor binding assay protocol is detailed in the literature for this compound. For triterpenoid saponins, typical cell-free assays include HCV protease inhibition assays using recombinant protease and fluorogenic substrates, or surface plasmon resonance (SPR) for binding affinity measurements. A general protocol involves incubating the compound with purified enzyme and substrate, then measuring fluorescence or absorbance changes.
|
| Cell Assay |
Cytotoxicity and antiproliferative activity are assessed using the MTT assay in rat HSC-T6 cells. Cells are seeded in 96-well plates, treated with serial dilutions of Deapioplatycodin D (e.g., 0.1-100 µM) for 48 hours, then MTT reagent is added and incubated for 4 hours. Formazan crystals are dissolved in DMSO and absorbance is measured at 570 nm to calculate IC50 values.
|
| Animal Protocol |
No detailed in vivo animal experimental protocol is publicly available for Deapioplatycodin D. For similar triterpenoid saponins, typical in vivo studies involve administration via oral gavage or intraperitoneal injection in rodent models of inflammation or viral infection, with endpoints including cytokine profiling, histopathological analysis, and viral load measurement.
|
| ADME/Pharmacokinetics |
DMSO solubility: 60-100 mg/mL; in vivo formulation: 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline (≥2.5 mg/mL). Powder stable at -20°C for 3 years, 4°C for 2 years; in solvent at -80°C for 6 months, -20°C for 1 month. Density: 1.5±0.1 g/cm³. Molecular weight: 1093.2.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural saponin, it is generally considered to have low toxicity, but standard safety pharmacology and toxicology studies (e.g., acute toxicity in rodents, Ames test for genotoxicity, hERG assay for cardiotoxicity) would be required for drug development.
|
| References | |
| Additional Infomation |
Deapio-platycodin D is a triterpenoid saponin that acts as a metabolite. It has been reported that Deapio-platycodin D is present in Platycodon grandiflorus, and relevant data are available for reference.
Deapioplatycodin D is a research-grade compound not approved for therapeutic use. It is primarily used as an analytical standard and for pharmacological research. Its mechanism involves inhibition of HCV protease and modulation of inflammatory pathways. No clinical trials or FDA approval have been reported; the compound remains in preclinical research stages. |
| Molecular Formula |
C52H84O24
|
|---|---|
| Molecular Weight |
1093.2090
|
| Exact Mass |
1092.535
|
| CAS # |
78763-58-3
|
| PubChem CID |
70698266
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Melting Point |
231-235 ℃
|
| Index of Refraction |
1.651
|
| LogP |
-0.39
|
| Hydrogen Bond Donor Count |
15
|
| Hydrogen Bond Acceptor Count |
24
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
76
|
| Complexity |
2100
|
| Defined Atom Stereocenter Count |
28
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H](CO[C@H]2OC(=O)[C@]34CCC(C[C@H]3C5=CC[C@H]6[C@]([C@@]5(C[C@H]4O)C)(CC[C@@H]7[C@@]6(C[C@@H]([C@@H](C7(CO)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)C)C)(C)C)O)O)O)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O
|
| InChi Key |
HCKUIVZXCXTBEH-PSRBGVDOSA-N
|
| InChi Code |
InChI=1S/C52H84O24/c1-21-39(73-42-36(65)31(60)25(57)17-69-42)35(64)38(67)43(71-21)74-40-32(61)26(58)18-70-45(40)76-46(68)52-12-11-47(2,3)13-23(52)22-7-8-28-48(4)14-24(56)41(75-44-37(66)34(63)33(62)27(16-53)72-44)51(19-54,20-55)29(48)9-10-49(28,5)50(22,6)15-30(52)59/h7,21,23-45,53-67H,8-20H2,1-6H3/t21-,23-,24-,25+,26-,27+,28+,29+,30+,31-,32-,33+,34-,35-,36+,37+,38+,39-,40+,41-,42-,43-,44-,45-,48+,49+,50+,52+/m0/s1
|
| Chemical Name |
[(2S,3R,4S,5S)-3-[(2S,3R,4S,5R,6S)-3,4-dihydroxy-6-methyl-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl] (4aR,5R,6aR,6aS,6bR,8aR,10R,11S,12aR,14bS)-5,11-dihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-10-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~91.47 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.29 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.29 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9147 mL | 4.5737 mL | 9.1474 mL | |
| 5 mM | 0.1829 mL | 0.9147 mL | 1.8295 mL | |
| 10 mM | 0.0915 mL | 0.4574 mL | 0.9147 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
